Featured Research

from universities, journals, and other organizations

COX-2 Enzyme Instrumental In Parkinson's Disease

Date:
April 8, 2003
Source:
Columbia University College Of Physicians And Surgeons
Summary:
Research by neurologists at Columbia University suggests that COX-2 inhibitors like Celebrex and Vioxx may someday help Parkinson's disease patients by preventing the death of neurons that characterizes the disease.

New York, NY, April 7, 2003 – Research by neurologists at Columbia University suggests that COX-2 inhibitors like Celebrex and Vioxx may someday help Parkinson's disease patients by preventing the death of neurons that characterizes the disease.

COX-2 enzymes are more familiar in arthritis, but the enzymes produce inflammation in all damaged tissues, including the brain. Many researchers now see the inflammation as a critical process in neurodegenerative diseases, and studies have shown that non-steroidal anti-inflammatory drugs (NSAIDS) reduce the risk of developing Alzheimer's disease.

To see if COX-2 plays a role in Parkinson's disease, Dr. Serge Przedborski, professor of neurology and pathology in the College of Physicians & Surgeons and faculty member in the Columbia University Center for Neurobiology and Behavior, and postdoctoral researcher Dr. Peter Teismann looked for the enzyme in postmortem brains of Parkinson's patients. They found higher levels of COX-2 in the dopamine neurons of patients than in the neurons of brains without the disease. Dopamine neurons suffer the most damage from the disease.

The researchers then tested the importance of COX-2 in mice that have a disease similar to Parkinson's. The mice have the same high level of COX-2 in their dopamine neurons as patients do, making the mouse a valuable model for studying the human disease.

COX-2 was found to have an instrumental role in the death of the neurons. When the COX-2 enzyme was removed from the mice, or inhibited with a COX-2 inhibitor, more dopamine neurons were able to survive. Rofecoxib, the COX-2 inhibitor, doubled the number of surviving neurons: 88 percent survived with the drug, while only 41 percent survived without the drug.

Surprisingly, however, the COX-2 enzyme does not kill neurons through inflammation. When the enzyme was removed from mice or inhibited with a drug, the researchers did not see the reduction in inflammation they expected to see.

Instead, they found that the COX-2 enzyme may kill by oxidizing other molecules in the dopamine neurons. The oxidized molecules then react with and damage other components of the cell. Excessive damage can kill the cell.

Many researchers have hypothesized that oxidative damage kills neurons in Parkinson's disease.

"Regardless of how COX-2 works in Parkinson's disease, the benefit we see in animal models with COX-2 inhibitors suggests the drugs could be useful in slowing the disease's progression in patients," Dr. Przedborski says. "The drugs are safe and they get into the brain reasonably well."

The National Institute on Aging sponsors a multi-center trial testing COX-2 inhibitors in Alzheimer's patients. Dr. Przedborski says researchers are planning new trials to test the drug in Parkinson's patients.

This study was funded, in part, by grants from the National institutes of Health/National Institute of Neurological Disorders and Stroke, the U.S. Department of Defense, and the Parkinson's Disease Foundation, New York.


Story Source:

The above story is based on materials provided by Columbia University College Of Physicians And Surgeons. Note: Materials may be edited for content and length.


Cite This Page:

Columbia University College Of Physicians And Surgeons. "COX-2 Enzyme Instrumental In Parkinson's Disease." ScienceDaily. ScienceDaily, 8 April 2003. <www.sciencedaily.com/releases/2003/04/030408085115.htm>.
Columbia University College Of Physicians And Surgeons. (2003, April 8). COX-2 Enzyme Instrumental In Parkinson's Disease. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2003/04/030408085115.htm
Columbia University College Of Physicians And Surgeons. "COX-2 Enzyme Instrumental In Parkinson's Disease." ScienceDaily. www.sciencedaily.com/releases/2003/04/030408085115.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Obama: Ebola Outbreak Threat to Global Security

Obama: Ebola Outbreak Threat to Global Security

AP (Sep. 16, 2014) President Obama is ordering U.S. military personnel to West Africa to deal with the Ebola outbreak, which is he calls a potential threat to global security. (Sept. 16) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins